Purpose/Objective: The prognostic value of standardized uptake value (SUV) distribution of the fluorine-18 labeled glucose analog (FDG), has been widely studied for the primary tumor in non-small cell lung cancer (NSCLC) patients. However, nodal stage determines treatment choice and is related to disease progression and its capability to metastasize. We hypothesize that more PET-related prognostic information can be extracted from affected hilar/mediastinal lymph nodes than in the primary tumor. Therefore, we analyzed the SUV distribution and volume of the primary tumor and affected lymph nodes prior to radiotherapy. Materials and Methods: A cohort of 352 stages I-III NSCLC patients referred for primary (chemo)radiotherapy was included. The gross tumor volume of the primary tumor (GTV prim ) and the metastatic lymph nodes (GTV ln ) had been manually delineated for treatment planning purposes. The nodal positive subset of patients (272) was selected for a comparison analysis based on volume and SUV descriptors (maximum, mean and peak), as derived from both the primary tumor and the affected lymph nodes, of the preradiotherapy PET scan. The prognostic value of each of the metrics to overall survival (OS), recorded from start of radiotherapy until last day of follow-up or death by any cause, was evaluated through a Cox Proportional Hazards regression.
Results:
We first compared the distribution of volume and common SUV descriptors of the primary tumor for N=0 (80) and N+ (272) NSCLC patients. The GTV prim of patients without affected lymph nodes was metabolically more active (SUV max = 13 ± 6.3; p<0.01, and SUV peak = 10.3 ± 5.1; p=0.02) and larger (volume = 127.3 ± 235.4; p < 0.01) than the GTV prim of patients with affected lymph nodes. Mean ranks difference (Wilcoxon test) of volume and SUV descriptors of both GTV prim and GTV ln was conducted for the nodal positive subset of patients, for which statistically significant (p<0.001) differences between metrics derived from the two structures could be shown (see table) . The prognostic value of each of the metrics to OS was evaluated through a Cox Proportional Hazards regression. None of the metrics derived from the primary tumor were associated with OS in our cohort. However, the same metrics, extracted from the involved lymph nodes, were prognostic for survival with mean SUV showing the strongest correlation with OS (HR=1.14, p < 0.01). Also, tumor load, defined as GTV prim + GTV ln showed a statistically significant correlation with OS. Currently, a multivariate analysis and collection of an external dataset for validation is ongoing.
Purpose/Objective: Stereotactic body radiotherapy (SBRT) is the treatment of choice in medically inoperable patients with stage I NSCLC. Today, SBRT is used with increasing frequency for pulmonary metastases: however, dose prescriptions are adapted from primary NSCLC experiences without their validation for metastases. It was therefore the aim of this study to analyze a potential dose-effect relationship for local tumor control in SBRT for pulmonary metastases and compare results to SBRT for stage I NSCLC.
Materials and Methods:
This retrospective multi-institutional study is based on 582 and 964 patients treated with SBRT for stage I NSCLC and pulmonary metastases at 13 centres; only patients with follow-up >6 months were analyzed resulting in 399 and 525 patients, respectively. Patients with primary NSCLC and pulmonary metastases were treated with a median of 3 (range 1-17) and 3 (1-12) fractions to a total dose of 60Gy (range 19-86) and 55Gy (16-80) (maximum PTV dose at isocenter; PTV-max), respectively. BED was calculated using the LQ-model with α/β=10Gy resulting in PTV-max doses of 168Gy (48-263) and 138Gy (24-288) BED for primary NSCLC and metastases, respectively. Dose-effect models were compared using the second-order bias corrected Akaike Information Citerion (AIC C ). We used Bayesian logistic regression to estimate regression parameters and their standard errors. Results: Median tumor diameter was 2.6cm (0.8-4.8) and 1.9cm (0.4-9.0) for patients with primary NSCLC and pulmonary metastases, respectively (p<0.001, Wilcoxon rank sum test); tumor diameter was lacking in 47% (primary NSCLC) and 12% (pulmonary metastases) of the patients. Most frequent histologies for pulmonary metastases were NSCLC (28%), colorectal (25%) and renal cell cancer (11%). Median follow-up was 19 months (6-139; primary NSCLC) and 16 months (6-125; pulmonary metastases) (p=0.15). For pulmonary metastases, a strong dose response relationship was observed (evidence ratio 98.6), but only for PTV-max BED and not for the PTV encompassing BED; the latter is in contrast to findings from SBRT for primary NSCLC, where a strong evidence for a minimum PTV dose-effect was observed (Guckenberger et al. Radiother Oncol 2013) . Overall, there was no difference in the dose response relationship between primary NSCLC and pulmonary metastases: the PTV-max BED required for 90% TCP was 176±17Gy and 167±18 Gy for primary NSCLC and pulmonary metastases, respectively. Conclusions: A significant dose-response relationship was observed in SBRT for pulmonary metastases with local tumor control as endpoint. The observed dose response relationship was not different to primary stage I NSCLC. We will, however, further investigate the influence of histology and tumor size on the dose-effect relationship in pulmonary metastases.
Symposium: Elderly should be treated as their younger counterparts
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The incidence of breast cancer is rising in the elderly, reflecting the age related incidence of the disease and, in the UK, the impact of the breast screening programme. The evidence base for the role of postoperative radiotherapy (RT) after breast conserving surgery in older patients has been limited, in part reflecting the historical exclusion of the elderly from randomised trials. Extrapolating outcomes from younger to older patients may not be valid. In older patients there are also competing risks of non breast cancer mortality. The Oxford overview (1) of over 10,000 women treated with breast conserving surgery with or without adjuvant radiotherapy shows that RT halves the risk of first recurrence (most of which are local). However the absolute reduction in risk of recurrence from RT is very modest in older good prognosis patients. The main source of level 1 evidence in older patients is the CALGB 9343 trial (1) which randomised over 700 women =/> 70 years with T1, NO,MO hormone receptor positive breast cancer treated by breast conserving
